GET DAILY SIGNALSWhy Did MannKind Corporation (MNKD) Stock Drop -36.82% Today?
Key Takeaways
- MNKD shares collapsed 36.82% on February 25, 2026, closing at $3.50 versus the prior session's close of $5.54 — one of the largest single-day declines in the stock's recent history
- The primary catalyst was United Therapeutics' surprise unveiling of Tresmi, a proprietary soft mist inhaler delivering treprostinil, announced during the company's Q4 2025 earnings call
- Tresmi directly threatens Tyvaso DPI, the dry powder inhaler developed by MannKind using its Technosphere platform, on which MannKind earns a 9% royalty on net sales
- Trading volume exploded to approximately 36.45 million shares — more than ten times the average daily volume of ~3.57 million shares, signaling widespread and urgent institutional selling
- MannKind also hit a new 52-week low of $3.29 intraday during the session
- Analysts are watching MannKind's upcoming Q4 2025 earnings report (due February 26, 2026), multiple FDA decision dates, and any management commentary on Tyvaso DPI royalty durability
Opening Summary
MannKind Corporation (MNKD) is a Westlake Village, California-based biopharmaceutical company that develops and commercializes inhaled therapeutic products, including Afrezza — the only inhaled, needle-free rapid-acting insulin approved for adults with diabetes — and FUROSCIX, a subcutaneous furosemide injection targeting heart failure patients. On February 25, 2026, MNKD shares plunged 36.82%, closing at $3.50 compared to the prior session's close of $5.54. The sell-off was triggered by a surprise announcement from partner United Therapeutics Corporation (UTHR) during its Q4 2025 earnings call, which unveiled a new competing inhaler product that markets deemed an existential threat to one of MannKind's most significant revenue streams.
The Tresmi Shock: What United Therapeutics Announced
During United Therapeutics' fourth-quarter 2025 earnings call on February 25, 2026, CEO Martine Rothblatt described the "unsheathing of a category killer product called Tresmi" — a proprietary drug-device formulation of treprostinil delivered via a soft mist inhaler. UTHR stated that Tresmi reduces coughing — the number-one side effect of dry powder inhalers — by up to 90% based on human studies conducted to date. The company said it plans to file for regulatory approval in pulmonary arterial hypertension (PAH) and interstitial lung disease (ILD) indications during 2026 and aims for a commercial launch in 2027. The candor of the announcement, including Rothblatt's assertion that "anyone would rather have soft mist than dry powder," left investors in MNKD with little ambiguity about the competitive intent.
Why This Devastates MannKind's Revenue Model
The direct link between Tresmi and MNKD's financials is MannKind's existing partnership with UTHR on Tyvaso DPI, a dry powder inhalation formulation of treprostinil approved by the FDA in 2022 for PAH and pulmonary hypertension associated with ILD. MannKind manufactures Tyvaso DPI at its Connecticut facility using its proprietary Technosphere inhaled-drug delivery technology and earns a 9% royalty on net sales — the company's single most significant royalty revenue stream. Should Tresmi successfully gain FDA approval and launch commercially in 2027, it could cannibalize Tyvaso DPI prescriptions and substantially erode the royalty income MNKD depends on. Critically, MannKind is not involved in the development of Tresmi in any capacity, meaning the company would receive no offsetting revenue from the new product if it displaces Tyvaso DPI.
Analyst Reaction: Legitimate Concerns, Possible Overreaction
Despite the severity of the sell-off, at least one Wall Street analyst urged investors not to panic. H.C. Wainwright analyst Brandon Folkes acknowledged that the drop reflects "legitimate concerns" about the potential shift in market dynamics for Tyvaso DPI, but argued the selloff may represent an overreaction that prices in a worst-case scenario well ahead of any proven commercial impact. The firm reiterated its Buy rating on MNKD and maintained a $11.00 price target. RBC Capital had previously flagged the United Therapeutics competitive dynamic as a "material risk" while keeping its Outperform rating intact, with a price target of $7.50. The analyst consensus heading into the session still averaged around $9.61–$10.86 in price targets across covered firms — figures that now sit dramatically above where the stock trades.
Market Context and Trading Activity
Volume in MNKD on February 25 surged to approximately 36.45 million shares traded, representing more than ten times the average daily volume of 3.57 million — a clear indicator of panic selling and institutional de-risking rather than routine price discovery. Intraday, shares hit a low of $3.29, which also marked a new 52-week low for the stock. The XBI biotech ETF experienced its own turbulence on the session, though the magnitude of MNKD's decline far exceeded broader sector weakness. From a technical perspective, the stock sliced through all meaningful support levels — its 20-day, 50-day, and 200-day simple moving averages — in a single session. The RSI-14 fell to approximately 19, placing MNKD deep in oversold territory and raising the possibility of a technical bounce, though momentum indicators continued to point downward at the close.
Liquidia Also Caught in the Crossfire
The competitive tremor from Tresmi was not limited to MannKind. Shares of Liquidia Corporation (LQDA), another company with treprostinil-based pulmonary hypertension assets, also fell sharply on the session as investors reassessed the competitive landscape for the entire inhaled treprostinil market. The Tresmi announcement effectively shifted the calculus for any company whose revenue or pipeline depends on treprostinil dry powder delivery, making the session's sector-wide collateral damage notable.
Trending AI Robots
For traders navigating extreme volatility events like the one seen in MNKD on February 25, Tickeron's Trending AI Robots page offers a curated view of the platform's highest-performing automated trading bots under current market conditions. Tickeron operates hundreds of AI-driven bots covering thousands of tickers, but only those demonstrating the strongest results given prevailing market dynamics are featured in the Trending section. These bots span a range of strategies — from momentum and breakout approaches to mean-reversion and swing-trading setups — and differ by timeframe, traded symbols, and performance metrics. Investors and active traders who want to complement their fundamental research with systematic, data-driven signals are encouraged to explore the Trending AI Robots page for tools suited to today's fast-moving environment.
What Comes Next for MNKD
The most immediate event on MNKD's calendar is its Q4 and full-year 2025 earnings report, released before market open on February 26, 2026, with a live management webcast scheduled at 9:00 a.m. ET. Investors will be listening intently for management's first official response to the Tresmi announcement, any quantification of potential royalty risk, and commentary on how the company plans to diversify revenue streams if Tyvaso DPI volumes come under sustained pressure. Beyond earnings, the May 29, 2026 FDA PDUFA date for the supplemental biologics license application for pediatric Afrezza use (ages 4–17) remains a potentially transformative approval, as does the July 26, 2026 FDA decision on the FUROSCIX ReadyFlow Autoinjector. MannKind is also advancing Nintedanib DPI (MNKD-201) through its INFLO-1 Phase 1b study, with a global Phase 2 study planned for the second quarter of 2026. The critical question for MNKD now is whether those pipeline assets and standalone commercial products can credibly offset the potential long-term erosion of its core Tyvaso DPI royalty income.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Financial writer and active order flow futures trader with a focus on fundamental analysis, macroeconomic factors, and equity research. I make in-depth blogs on stocks and ETFs, bridging the gap between raw market data and real-world trading decisions.
Momentum Indicator for MNKD turns positive, indicating new upward trend
MNKD saw its Momentum Indicator move above the 0 level on October 26, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 92 similar instances where the indicator turned positive. In 79 of the 92 cases, the stock moved higher in the following days. The odds of a move higher are at 86%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Moving Average Convergence Divergence (MACD) for MNKD just turned positive on October 23, 2026. Looking at past instances where MNKD's MACD turned positive, the stock continued to rise in 38 of 48 cases over the following month. The odds of a continued upward trend are 79%.
MNKD moved above its 50-day moving average on November 02, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +7.67% 3-day Advance, the price is estimated to grow further. Considering data from situations where MNKD advanced for three days, in 203 of 255 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.
Bearish Trend Analysis
The RSI Indicator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 7 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where MNKD declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 79%.
MNKD broke above its upper Bollinger Band on November 04, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for MNKD entered a downward trend on October 14, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 4 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-18.805) is normal, around the industry mean (2.904). P/E Ratio (-26.200) is within average values for comparable stocks, (-0.738). Projected Growth (PEG Ratio) (0.220) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (128.314) among similar stocks. P/S Ratio (2.832) is also within normal values, averaging (440.869).
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 60 (best 1 - 100 worst), indicating steady price growth. MNKD’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 98 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MNKD’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of therapeutic products
Industry Biotechnology
Advertisement